WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  July 14, 2004

 

ARENA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

6166 Nancy Ridge Drive, San Diego, California 92121

(Address of Principal Executive Offices)   (Zip Code)

 

(858) 453-7200

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Item 5.  Other Events.

 

On July 14, 2004, Arena Pharmaceuticals, Inc., a Delaware corporation, issued a press release announcing Phase 1a safety and clinical pharmacology trial results.  A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 7.  Financial Statements and Exhibits.

 

(c)                                  Exhibits.

 

99.1                           Press release issued July 14, 2004, announcing Phase 1a safety and clinical pharmacology trial results.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  July 14, 2004	Arena Pharmaceuticals, Inc.,
	a Delaware corporation
	By:	/s/ Jack Lief
		Jack Lief
		President & Chief Executive Officer

 

2

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release issued July 14, 2004, announcing Phase 1a safety and clinical pharmacology trial results.

 

3